{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T10:51:38Z","timestamp":1769511098150,"version":"3.49.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100011495","name":"Massachusetts Life Sciences Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011495","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.diabres.2023.110870","type":"journal-article","created":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T15:28:23Z","timestamp":1691594903000},"page":"110870","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["The first external validation of the Dallas steatosis index in biopsy-proven Non-alcoholic fatty liver Disease: A multicenter study"],"prefix":"10.1016","volume":"203","author":[{"given":"Matina","family":"Kouvari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophia C.","family":"Mylonakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angeliki","family":"Katsarou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3824-6546","authenticated-orcid":false,"given":"Laura","family":"Valenzuela-Vallejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Guatibonza-Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0027-5659","authenticated-orcid":false,"given":"Michail","family":"Kokkorakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ornella","family":"Verrastro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Angelini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Markakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Eslam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"George","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Papatheodoridis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geltrude","family":"Mingrone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos S.","family":"Mantzoros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2023.110870_b0005","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatol Baltim Md"},{"issue":"4","key":"10.1016\/j.diabres.2023.110870_b0010","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3350\/cmh.2022.0239","article-title":"Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach","volume":"28","author":"Le","year":"2022","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.diabres.2023.110870_b0015","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13098-020-00570-y","article-title":"NAFLD as a continuum: from obesity to metabolic syndrome and diabetes","volume":"12","author":"Godoy-Matos","year":"2020","journal-title":"Diabetol Metab Syndr"},{"issue":"10","key":"10.1016\/j.diabres.2023.110870_b0020","first-page":"2296","article-title":"Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)\/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry","volume":"20","author":"Younossi","year":"2022","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"issue":"5","key":"10.1016\/j.diabres.2023.110870_b0025","first-page":"3314","article-title":"Mediterranean diet is inversely associated with steatosis and fibrosis and decreases ten-year diabetes and cardiovascular risk in NAFLD subjects: Results from the ATTICA prospective cohort study","volume":"40","author":"Kouvari","year":"2021","journal-title":"Clin Nutr Edinb Scotl"},{"key":"10.1016\/j.diabres.2023.110870_b0030","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.diabres.2023.110870_b0035","first-page":"1877","article-title":"Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage","volume":"17","author":"Siddiqui","year":"2019","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"10.1016\/j.diabres.2023.110870_b0040","article-title":"Advances in non-invasive biomarkers for the diagnosis and monitoring of non-alcoholic fatty liver disease","volume":"111S","author":"Long","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.diabres.2023.110870_b0045","article-title":"The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease","volume":"111S","author":"Perakakis","year":"2020","journal-title":"Metabolism"},{"issue":"6","key":"10.1016\/j.diabres.2023.110870_b0050","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.jhep.2020.06.025","article-title":"Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials","volume":"73","author":"Davison","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.diabres.2023.110870_b0055","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","article-title":"Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease","volume":"156","author":"Castera","year":"2019","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.diabres.2023.110870_b0060","doi-asserted-by":"crossref","DOI":"10.1186\/s12944-017-0409-6","article-title":"The triglyceride and glucose index (TyG) is an effective biomarker to identify nonalcoholic fatty liver disease","volume":"16","author":"Zhang","year":"2017","journal-title":"Lipids Health Dis"},{"issue":"3","key":"10.1016\/j.diabres.2023.110870_b0065","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1053\/j.gastro.2009.06.005","article-title":"Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors","volume":"137","author":"Kotronen","year":"2009","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.diabres.2023.110870_b0070","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jceh.2019.07.002","article-title":"Natural History of Non-Alcoholic Fatty Liver Disease: A Study With Paired Liver Biopsies","volume":"10","author":"Reddy","year":"2020","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.diabres.2023.110870_b0075","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/1471-230X-10-98","article-title":"A simple index of lipid overaccumulation is a good marker of liver steatosis","volume":"10","author":"Bedogni","year":"2010","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.diabres.2023.110870_b0080","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1111\/apt.12963","article-title":"Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease","volume":"40","author":"Fedchuk","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.diabres.2023.110870_b0085","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.21037\/qims-21-895","article-title":"Ultrasonographic index for the diagnosis of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease","volume":"12","author":"Kim","year":"2022","journal-title":"Quant Imaging Med Surg"},{"key":"10.1016\/j.diabres.2023.110870_b0090","first-page":"2073","article-title":"Dallas Steatosis Index Identifies Patients With Nonalcoholic Fatty Liver Disease","volume":"18","author":"McHenry","year":"2020","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"10.1016\/j.diabres.2023.110870_b0095","first-page":"2638","article-title":"Validation of the Dallas Steatosis Index to Predict Nonalcoholic Fatty Liver Disease in the UK Biobank Population","volume":"20","author":"McHenry","year":"2022","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"10.1016\/j.diabres.2023.110870_b0100","doi-asserted-by":"crossref","first-page":"155666","DOI":"10.1016\/j.metabol.2023.155666","article-title":"Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive non-alcoholic fatty liver disease indexes: Results from a large multi-center study","author":"Kouvari","year":"2023","journal-title":"Metabolism"},{"issue":"10390","key":"10.1016\/j.diabres.2023.110870_b0105","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1016\/S0140-6736(23)00634-7","article-title":"Bariatric\u2013metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial","volume":"401","author":"Verrastro","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2023.110870_b0110","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2307\/2531595","article-title":"Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach","volume":"44","author":"DeLong","year":"1988","journal-title":"Biometrics"},{"key":"10.1016\/j.diabres.2023.110870_b0115","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/0272989X06295361","article-title":"Decision curve analysis: a novel method for evaluating prediction models","volume":"26","author":"Vickers","year":"2006","journal-title":"Med Decis Mak Int J Soc Med Decis Mak"},{"key":"10.1016\/j.diabres.2023.110870_b0120","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1007\/s10620-022-07415-w","article-title":"Accuracy of Non-invasive Indices for Diagnosing Hepatic Steatosis Compared to Imaging in a Real-World Cohort","volume":"67","author":"DiBattista","year":"2022","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.diabres.2023.110870_b0125","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.amjmed.2020.08.010","article-title":"The Impact of Nonalcoholic Fatty Liver Disease in Primary Care: A Population Health Perspective","volume":"134","author":"Dokmak","year":"2021","journal-title":"Am J Med"},{"issue":"6","key":"10.1016\/j.diabres.2023.110870_b0130","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jhep.2019.08.019","article-title":"Transient elastography for screening of liver fibrosis: Cost-effectiveness analysis from six prospective cohorts in Europe and Asia","volume":"71","author":"Serra-Burriel","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.diabres.2023.110870_b0135","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/apt.14967","article-title":"Liver fat scores predict liver disease mortality in the United States population","volume":"48","author":"Unalp-Arida","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.diabres.2023.110870_b0140","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.cca.2017.01.008","article-title":"Associations of the fatty liver and hepatic steatosis indices with risk of cardiovascular disease: Interrelationship with age","volume":"466","author":"Kunutsor","year":"2017","journal-title":"Clin Chim Acta Int J Clin Chem"},{"key":"10.1016\/j.diabres.2023.110870_b0145","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/dom.14923","article-title":"Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium-glucose cotransporter-2 inhibitor ertugliflozin","volume":"25","author":"Corbin","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2023.110870_b0150","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/jcsm.12719","article-title":"Non-alcoholic fatty liver disease and sarcopenia additively increase mortality: a Korean nationwide survey","volume":"12","author":"Moon","year":"2021","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.diabres.2023.110870_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154893","article-title":"The presence of NAFLD influences the transition of metabolically healthy to metabolically unhealthy obesity and the ten-year cardiovascular disease risk: A population-based cohort study","volume":"128","author":"Kouvari","year":"2022","journal-title":"Metabolism"},{"issue":"6","key":"10.1016\/j.diabres.2023.110870_b0160","first-page":"1281","article-title":"Skeletal muscle mass and abdominal obesity are independent predictors of hepatic steatosis and interact to predict ten-year cardiovascular disease incidence: Data from the ATTICA cohort study","volume":"41","author":"Kouvari","year":"2022","journal-title":"Clin Nutr Edinb Scotl"},{"issue":"1","key":"10.1016\/j.diabres.2023.110870_b0165","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-020-01025-4","article-title":"Fatty liver index and development of cardiovascular disease in Koreans without pre-existing myocardial infarction and ischemic stroke: a large population-based study","volume":"19","author":"Kim","year":"2020","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.diabres.2023.110870_b0170","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-022-01691-6","article-title":"The association of fatty liver index and BARD score with all-cause and cause-specific mortality in patients with type 2 diabetes mellitus: a nationwide population-based study","volume":"21","author":"Chung","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.diabres.2023.110870_b0175","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-022-01483-y","article-title":"The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study","volume":"21","author":"Park","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabres.2023.110870_b0180","doi-asserted-by":"crossref","first-page":"110191","DOI":"10.1016\/j.diabres.2022.110191","article-title":"The association between changes in hepatic steatosis and hepatic fibrosis with cardiovascular outcomes and mortality in patients with New-Onset type 2 Diabetes: A nationwide cohort study","volume":"194","author":"Park","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"10.1016\/j.diabres.2023.110870_b0185","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-021-01374-8","article-title":"The association of hepatic steatosis and fibrosis with heart failure and mortality","volume":"20","author":"Park","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabres.2023.110870_b0190","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.638615","article-title":"The Repeatedly Elevated Fatty Liver Index Is Associated With Increased Mortality: A Population-Based Cohort Study","volume":"12","author":"Lee","year":"2021","journal-title":"Front Endocrinol"},{"issue":"7","key":"10.1016\/j.diabres.2023.110870_b0195","first-page":"899","article-title":"Prediction of Cardiovascular Risk Using Nonalcoholic Fatty Liver Disease Scoring Systems","volume":"9","author":"Kweon","year":"2021","journal-title":"Healthc Basel Switz"},{"key":"10.1016\/j.diabres.2023.110870_b0200","doi-asserted-by":"crossref","first-page":"155222","DOI":"10.1016\/j.metabol.2022.155222","article-title":"Association of fatty liver index with all-cause and disease-specific mortality: A nationwide cohort study","volume":"133","author":"Chung","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.diabres.2023.110870_b0205","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1097\/MEG.0000000000001183","article-title":"Association of fatty liver index with the risk of incident cardiovascular disease and acute myocardial infarction","volume":"30","author":"Olubamwo","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.diabres.2023.110870_b0210","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1007\/s10620-021-06954-y","article-title":"Fatty Liver Index and Development of Cardiovascular Disease: Findings from the UK Biobank","volume":"66","author":"Zou","year":"2021","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.diabres.2023.110870_b0215","doi-asserted-by":"crossref","first-page":"109208","DOI":"10.1016\/j.diabres.2022.109208","article-title":"Long-term effects of the changes in hepatic steatosis status on the risk of incident type 2 diabetes mellitus: A 15-year community-based prospective cohort study","volume":"184","author":"Chung","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"issue":"23","key":"10.1016\/j.diabres.2023.110870_b0220","first-page":"00326","article-title":"Fibrosis-4 Index Predicts Long-Term All-Cause, Cardiovascular and Liver-Related Mortality in the Adult Korean Population","volume":"S1542\u20133565","author":"Seo","year":"2023","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822723006332?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822723006332?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T03:45:41Z","timestamp":1736394341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822723006332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":44,"alternative-id":["S0168822723006332"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2023.110870","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The first external validation of the Dallas steatosis index in biopsy-proven Non-alcoholic fatty liver Disease: A multicenter study","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2023.110870","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110870"}}